🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Spain
Clinical trial register · European Union · CTIS

Clinical Trials in Spain, 2026

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12490 total CTIS records — a stated recency window, not the full historical archive. Synced 25 Sep 2026, 03:16 UTC
2500
Shown in this register
most recently authorised
12,490
Total on CTIS
full historical archive
741
Phase III
within the shown window
Top member states
Spain 1016 France 881 Germany 860 Italy 735 Poland 585 Netherlands 531
Narrow the registerReset
Phase
Phase I 554 Phase I/II 213 Phase II 733 Phase III 741 Phase IV 259
Lead sponsor
AstraZeneca AB 62 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 48 Pfizer Inc. 44 Novo Nordisk A/S 43
Member state
Spain 1016 France 881 Germany 860 Italy 735 Poland 585 Netherlands 531 Belgium 434 Czechia 327
All 28 states

Trials with a site in Spain

1016 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase II
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of V940 in Combination With Pembrolizumab and Chemotherapy as First-Line Treatment for Participants With Metastatic Squamous NSCLC (INTerpath-013)
2025-520902-37-00Non-small cell lung cancer stage IV
Merck Sharp & Dohme LLC
Neoplasms
Italy, Spain, Poland, France
23/03/2026
Phase III
Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02).
2025-523085-24-00Biliary Tract Cancer
AstraZeneca AB
Neoplasms
Germany, Poland, Italy, Belgium, France, Netherlands, Spain
23/03/2026
Phase III
A Phase 3, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre Study With a Double-Blind Extension Evaluating Efficacy and Safety of Lebrikizumab Administered to Adult Patients With Nummular Eczema who are not Adequately Controlled With Topical Corticosteroids or When This Treatment is not Medically Advisable (LUMINE)
2025-522403-17-00Nummular Dermatitis
Almirall S.A.
Skin and Connective Tissue Diseases
Italy, Bulgaria, Spain, Germany, Poland, France
23/03/2026
Phase II
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib plus Ribociclib plus Fulvestrant Versus Placebo plus Ribociclib plus Fulvestrant in Patients with Endocrine-Resistant Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer with Chromosome 8P Loss and Without a PIK3CA Mutation
2025-523013-28-00Endocrine-Resistant Hormone-Receptor-Positive, HER2-Negativ…
F. Hoffmann-La Roche AG
Neoplasms
France, Italy, Poland, Germany, Spain
23/03/2026
Phase II
A Phase 2 Study of ACR-368 Therapy in Subjects with Endometrial Cancer
2025-524542-10-00Endometrial cancer
Acrivon Therapeutics Inc.
Neoplasms
Italy, Germany, Spain, France
23/03/2026
Phase I
A clinical study to test MEN2501 in patients with treatment-resistant ovarian cancer
2025-524168-39-00​​Platinum-Resistant ovarian cancer​
Stemline Therapeutics Inc.
Neoplasms
Spain
23/03/2026
Phase III
C6461003 - AN INTERVENTIONAL, PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER
2025-523521-18-00Metastatic Colorectal Cancer
Pfizer Inc.
Neoplasms
Spain, Belgium, France, Italy, Netherlands, Germany, Poland, Denmark
23/03/2026
Phase I
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
2024-519862-33-01Platinum-resistant ovarian cancer (PROC), Advanced renal ce…
Oncusp Therapeutics Inc.
Neoplasms
Denmark, Spain
23/03/2026
Phase II
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants with Active Psoriatic Arthritis
2025-523141-10-00Active Psoriatic Arthritis
Janssen Cilag International
Immune System Diseases
Spain, Poland, Czechia, Germany, Hungary
20/03/2026
Phase II
A Phase 2 Posology Study with Long-Term Extension in Participants with Well‑Controlled Recurrent Pericarditis to Evaluate the Efficacy and Safety of Transition Regimens to KPL-387 Monotherapy from Standard Therapies
2025-523234-66-00Well-Controlled Recurrent Pericarditis
Kiniksa Pharmaceuticals GmbH
Therapeutics
Spain, Greece, Germany, France, Italy, Poland
19/03/2026
Phase I
Phase 1 trial of valemetostat and darolutamide in mCRPC
2025-522512-16-00Metastatic Castration Resistant Prostate Cancer (mCRPC)
Daiichi Sankyo Inc.
Neoplasms
Ireland, Spain, France
18/03/2026
Phase II
SEZanne: A Phase 2 Randomized, Open label, Multicenter Study to Evaluate the Optimal Dose, Safety, and Efficacy of ABBV-706 in Combination with Atezolizumab versus Standard of Care as First-Line Treatment in Subjects with Previously Untreated Extensive Stage Small Cell Lung Cancer (ES-SCLC)
2024-517490-24-00Small Cell Lung Cancer
AbbVie Deutschland GmbH & Co. KG
Neoplasms
Spain, Germany, Italy, Poland, Belgium
18/03/2026
Phase II
J6E-MC-KWAN: A Phase 2, Multicenter, Randomized, Double-Blind, Active-Controlled Study of LY4268989 (MORF-057) Co-Administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis
2025-522338-30-00Ulcerative Colitis
Eli Lilly & Co.
Digestive System Diseases
Hungary, Spain, Denmark, Netherlands, Poland, Romania, Germany, Italy, Austria
18/03/2026
Phase II
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic Effects of REGN13335, an Anti-PDGF-B Monoclonal Antibody, in Adults with Pulmonary Arterial Hypertension
2024-514754-79-00Pulmonary Arterial Hypertension (PAH)
Regeneron Pharmaceuticals Inc.
Cardiovascular Diseases
Latvia, Belgium, France, Poland, Germany, Spain, Czechia
18/03/2026
Phase III
A Phase 3, Randomized, Double-blind, Placebo-controlled, 3-Part Study to Evaluate the Efficacy and Safety of Orally Administered Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-demand Treatment of Angioedema Attacks in Adults with Acquired Angioedema due to C1 Inhibitor Deficiency
2025-522051-26-00Acquired Angioedema due to C1 Inhibitor Deficiency
Pharvaris Netherlands B.V.
Immune System Diseases
Hungary, Spain, Austria, Germany, Poland, Netherlands, France, Italy, Bulgaria
17/03/2026
Phase II
An open-label, uncontrolled, multicenter study to assess the effect of zigakibart treatment on histologic, circulating, and excreted markers of kidney disease and dysfunction in adult patients with IgA nephropathy
2024-519699-24-00IgA nephropathy
Novartis Pharma AG
Immune System Diseases
Czechia, Germany, Spain, Italy, Poland
17/03/2026
Phase IV
Use of half the iodinated contrast medium for monitoring thoracic neoplasms using spectral CT: Randomized, crossover, non-inferiority clinical trial
2025-524901-33-00Thoracic neoplasm
Fundacion De La Comunitat Valenciana Para La Gestion Del Instituto De Investigacion Sanitaria Y Biomedica De Alicante
Diagnosis
Spain
17/03/2026
Phase I/II
A Phase 1/2 Trial of RPTR-1-201, a T Cell Receptor Bispecific Therapy, in Advanced Solid Tumors
2025-524010-28-00Advanced Solid Tumor
Repertoire Immune Medicines Inc.
Neoplasms
Spain, Ireland, Portugal, France
17/03/2026
Phase II
A Phase 2, Randomized, Masked, Placebo-Controlled Study of Subcutaneously Administered ADX-038 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
2025-521779-30-00Geographic atrophy secondary to age-related macular degener…
Adarx Pharmaceuticals Inc.
Eye Diseases
Germany, Portugal, Italy, Spain
17/03/2026
Phase I/II
A Phase Ib/II, Multicenter, Open-Label Study to Evaluate Safety, Efficacy, and Pharmacokinetics of YL201 in Combination with Other Anti-Cancer Therapies in Patients with Advanced Solid Tumors
2025-523742-27-00Advanced solid tumors
Medilink Therapeutics (Suzhou) Co. Ltd.
Neoplasms
Poland, Spain, France, Romania, Italy, Belgium, Hungary, Germany
17/03/2026
Phase III
A multicentre, randomised, double-blind, parallel group, placebo-controlled trial to assess the effects of oral TRPC6 inhibitor BI 764198 taken over a 104 week treatment period in adult and adolescent participants with primary focal segmental glomerulosclerosis (pFSGS) or genetic FSGS related to TRPC6 gene variants
2025-522191-86-00Focal segmental glomerulosclerosis
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Female Urogenital Diseases and Pregnancy Complications
Germany, Croatia, Poland, Sweden, Portugal, Netherlands, Italy, Denmark, Slovakia, Spain, Norway, Romania, Belgium, Greece, France
17/03/2026
Phase I
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
2025-523686-15-00Advanced or Metastatic Solid Tumors
Olema Pharmaceuticals Inc.
Neoplasms
Ireland, Spain, France
17/03/2026
Phase III
A Phase 3b Long-term Efficacy and Safety Extension Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria Who Have Completed CDX0159-12 or CDX0159-13 (EMBARQ-CSU LTE)
2025-522878-36-00Chronic Spontaneous Urticaria
Celldex Therapeutics Inc.
Skin and Connective Tissue Diseases
Croatia, France, Netherlands, Bulgaria, Portugal, Slovakia, Hungary, Italy, Greece, Germany, Czechia, Lithuania, Spain, Belgium, Denmark, Poland
16/03/2026
Phase II
An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of Weekly Intravenous Infusions of BMN 351 in Participants with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
2024-511656-41-00Duchenne Muscular Dystrophy
Biomarin Pharmaceutical Inc.
Musculoskeletal Diseases
Spain, Italy, Netherlands
16/03/2026
Phase II
A Phase 2 Study of Emavusertib in Combination with an Approved Bruton Tyrosine Kinase Inhibitor in Patients with Chronic Lymphocytic Leukemia and Other B-cell Malignancies
2025-523600-68-00Chronic Lymphocytic Leukemia and Other B-cell Malignancies
Curis Inc.
Neoplasms
Spain, Italy
16/03/2026
Phase I
Phase 1 open label trial of MST-0312 alone and in combination in subjects with solid malignancies
2025-524446-10-00Solid Malignancies
Mestag Therapeutics Limited
Neoplasms
Spain
13/03/2026
Phase IV
Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis (UP-FOR-U)
2025-522118-21-00Axial Spondyloarthritis, Acute Anterior Uveitis
Care Arthritis Ltd.
Eye Diseases
Spain, Poland, Netherlands, France, Bulgaria, Germany
13/03/2026
Phase II
A phase 2b, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of Usnoflast administered to adult subjects with Amyotrophic Lateral Sclerosis (ALS)
2025-522580-15-00Amyotrophic Lateral Sclerosis (ALS)
Zydus Therapeutics Inc.
Nervous System Diseases
Spain, Germany, Sweden, Ireland, Poland, Italy, Belgium, France, Netherlands
12/03/2026
Phase I
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects with Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study
2024-512515-45-01Non-Small Cell Lung Cancer
Theras Inc.
Neoplasms
Spain, Denmark
12/03/2026
Phase I
A Phase 1a/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of BG-75202, Alone and in Combination with Other Agents in Patients with Advanced Solid Tumors
2025-523553-34-00Advanced and Metastatic Solid tumors
BeOne Medicines I GmbH
Neoplasms
Italy, Spain
12/03/2026
Phase I
A Study to Evaluate the Safety and Tolerability of ARV-806 in Adults with Advanced Cancer that has the KRAS G12D Mutation
2025-521062-10-00KRAS G12D Mutated Advanced Solid Tumors
Arvinas Operations Inc.
Neoplasms
Spain, Italy
12/03/2026
Phase I
Safety and Preliminary Efficacy of CTX112 in Adult Participants with Relapsed/Refractory Hematologic Autoimmune Disease
2025-523845-90-00Relapsed/Refractory Hematologic Autoimmune Disease
CRISPR Therapeutics AG
Hemic and Lymphatic Diseases
Spain, Germany, France, Denmark, Italy, Netherlands
12/03/2026
Phase III
A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (WHO Group 3)
2024-517943-29-00Pulmonary Hypertension associated with interstitial lung di…
Liquidia Technologies Inc.
Respiratory Tract Diseases
Latvia, Germany, Italy, Czechia, France, Belgium, Portugal, Poland, Austria, Spain
11/03/2026
Phase II
INTRATUMORAL DNX-2401 ADMINISTRATION FOR RECURRENT AND REFRACTORY HIGH GRADE BRAIN TUMORS IN PEDIATRIC AND YOUNG ADULT PATIENTS
2024-515009-24-00High grade malignant brain neoplasm
Clinica Universidad De Navarra
Nervous System Diseases
Netherlands, Spain
11/03/2026
Phase III
TENACITY – A Phase III, prospective, randomized, open-label, blinded endpoint assessment (PROBE) to assess efficacy and safety of i.v. tenecteplase vs standard of care in patients with acute ischemic stroke (including wake-up stroke), last known well >4.5 h with imaging evidence of salvageable ischemic tissue
2025-522542-40-00Acute Ischemic Stroke
Boehringer Ingelheim International GmbH
Cardiovascular Diseases
Greece, Norway, Hungary, Romania, Spain, Bulgaria
11/03/2026
Phase II
B7981119 A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 16-Week Study Evaluating the Safety and Efficacy of Ritlecitinib (PF-06651600) in Adults with Moderate to Severe Hidradenitis Suppurativa
2025-522705-37-00HIDRADENITIS SUPPURATIVA
Pfizer Inc.
Skin and Connective Tissue Diseases
Germany, Poland, Spain, Greece
11/03/2026
Phase III
Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing adjuvant Elacestrant with standard endocrine treatment in genomically and/or clinically high-risk ER+/HER2- early breast cancer (ADAPTela)
2025-522484-15-00ER+/HER2- early breast cancer
WSG Women's Cancer Study Group GmbH
Neoplasms
Germany, Spain, Austria
11/03/2026
Phase III
ROSETTA Gastric-204: A Blinded, Randomized, Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy in Participants with Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
2025-523263-37-00Previously Untreated Advanced or Metastatic Gastric, Gastro…
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Germany, Spain, Poland, France, Italy, Romania
10/03/2026
Phase III
ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination with Chemotherapy in Participants with Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
2025-523224-45-00Untreated, Unresectable or Metastatic Colorectal Cancer
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Sweden, Czechia, Belgium, Romania, Netherlands, Italy, France, Spain, Germany, Poland, Austria
10/03/2026
Phase III
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Azetukalner in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
2025-522775-29-00Depressive episodes associated with Bipolar disorder I or I…
Xenon Pharmaceuticals Inc.
Mental Disorders
Germany, Bulgaria, Spain, Poland
10/03/2026
Phase I
The clinical trial to study a new drug, AP-2.
2025-524480-21-00ALS and related disorders like frontotemporal dementia and …
Molefy Pharma S.L.
Nervous System Diseases
Spain
10/03/2026
Phase II
A Phase 2a Multicenter Platform Study of Investigational Products for the Treatment of Adult Subjects with Idiopathic Pulmonary Fibrosis
2024-518013-25-00Idiopathic Pulmonary Fibrosis
AbbVie Deutschland GmbH & Co. KG
Respiratory Tract Diseases
Greece, Italy, Sweden, Germany, Portugal, Spain, France, Hungary, Poland, Bulgaria, Romania
10/03/2026
Phase III
REVEAL Study: Phase 3 Study of the Efficacy and Safety of ION582 in Children and Adults with Angelman Syndrome
2024-519711-33-01Angelman syndrome
Ionis Pharmaceuticals Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Italy, Germany, Poland, Spain
09/03/2026
Phase III
A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer
2025-522713-29-00Metastatic Castration-resistant Prostate Cancer (mCRPC)
Janssen Cilag International
Neoplasms
Belgium, Italy, Spain, Germany, France
09/03/2026
Phase II
A Phase II, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy and Safety of the Combination of Inavolisib Plus Enzalutamide Versus Physician's Choice of ARPI or Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer
2025-521327-67-00Metastatic Castration-Resistant Prostate Cancer
F. Hoffmann-La Roche AG
Neoplasms
Germany, France, Italy, Spain
06/03/2026
Phase I/II
An Adaptive Dose Escalation and Expansion Basket Trial to Explore the Safety, Pharmacology, and Clinical Activity of TGD001 in Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP) and Other Thrombotic Microangiopathies
2025-523802-34-00Immune-Mediated Thrombotic Thrombocytopenic Purpura, Thromb…
TargED Biopharmaceuticals B.V.
Hemic and Lymphatic Diseases
Germany, France, Italy, Spain
06/03/2026
Phase II
A multinational, multicenter extension study to investigate the long-term safety, tolerability and efficacy of balinatunfib in adults with Crohn’s disease or ulcerative colitis
2025-522511-42-00Crohn's disease, Colitis Ulcerative
Sanofi-Aventis Recherche & Developpement
Digestive System Diseases
Belgium, Germany, Czechia, Netherlands, Spain, Austria, Italy, Greece, Croatia, Bulgaria, Poland, France, Romania, Hungary
06/03/2026
Phase I
A Study of PHN-012 in Patients With Advanced Solid Tumors
2025-523756-31-00Advanced Solid Tumors
Pheon Therapeutics Limited
Neoplasms
Spain
06/03/2026
Phase I/II
A phase Ib/II open-label, multi-center study of the DNA protein kinase inhibitor AMO959 with lutetium (177Lu) vipivotide tetraxetan (AAA617) in combination with an androgen receptor pathway inhibitor (ARPI) in adult participants with PSMA-positive metastatic castration resistant prostate cancer (mCRPC)
2025-521859-23-00PSMA-positive mCRPC with prior exposure to at least one pri…
Novartis Pharma AG
Neoplasms
Germany, France, Spain, Italy
05/03/2026
Phase IV
Botulinum toxin in open abdomen closure. A multicentric randomized controlled single-blind clinical trial to evaluate the efficacy of early administration of botulinum toxin for primary midline closure in patients with an open abdomen.
2025-522410-23-00open abdomen
Hospital Universitario La Paz
Not possible to specify
Spain
04/03/2026
Phase III
A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy versus placebo with chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic TNBC determined ineligible for PD(L)1 therapy based on PD-L1 negative disease
2025-521884-12-00First line triple-negative breast cancer (TNBC)
BioNTech SE
Neoplasms
Czechia, Poland, Italy, France, Belgium, Netherlands, Germany, Spain
04/03/2026
Phase I/II
Protocol Title: KEYMAKER-U01 Substudy 01F: A Phase 1b/2 Umbrella Study With Rolling Arms of Investigational Agents for Previously Treated of Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With KRAS G12C Mutations
2024-512248-47-00Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC
Neoplasms
Italy, Germany, Greece, Poland, Hungary, Spain
04/03/2026
Phase I
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
2025-523232-39-00Advanced Solid Tumors
Merck Healthcare KGaA
Neoplasms
Spain
03/03/2026
Phase III
A randomized, double-blind, placebo-controlled Phase III study to evaluate the efficacy and safety of remibrutinib in patients with secondary progressive multiple sclerosis
2025-521546-23-00Secondary progressive multiple sclerosis
Novartis Pharma AG
Nervous System Diseases
Denmark, Slovenia, Netherlands, Portugal, Ireland, Sweden, Croatia, Greece, Germany, Latvia, Czechia, Spain, Romania, Belgium, Austria, Lithuania, Slovakia, Poland, Estonia, Bulgaria, France, Italy, Hungary, Finland, Norway
03/03/2026
Phase III
A double blind, randomized, placebo-controlled exploratory trial to investigate the efficacy and safety of nerandomilast over 24 months when administered in individuals with interstitial lung abnormalities and a family history of pulmonary fibrosis to reduce the risk of worsening (DROP-FPF)
2025-522383-33-00Pulmonary fibrosis, Interstitial lung diseases, Familial pu…
Boehringer Ingelheim International GmbH
Respiratory Tract Diseases
Belgium, Spain, Netherlands, Italy, Germany, France
03/03/2026
Phase III
A prospective, open-label, single-arm, multicenter study evaluating the efficacy of Xanomeline/Trospium (XT) on cognitive impairment after 24 and 52 weeks of treatment in adult participants with schizophrenia.
2025-523060-20-00Schizophrenia
European Group for Research in Schizophrenia Stichting
Mental Disorders
Denmark, Belgium, Italy, Netherlands, Hungary, Czechia, Austria, Spain, Germany
03/03/2026
Phase I/II
A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD9793, a T cell-engaging Antibody Targeting Glypican-3 (GPC3) in Adult Participants with Advanced or Metastatic Solid Tumours (RHEA-1)
2024-516698-56-00Hepatocellular Carcinoma
AstraZeneca AB
Neoplasms
Spain
03/03/2026
Phase I
C6001001 - A Study to Learn about the Study Medicine PF-08052667 in People with Bladder Cancer.
2025-521756-39-00Non-muscle invasive bladder cancer (NMIBC)
Pfizer Inc.
Neoplasms
France, Spain
02/03/2026
Phase II
A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease
2025-521752-26-00Complement-Mediated Kidney Disease
Adarx Pharmaceuticals Inc.
Male Urogenital Diseases
Spain, Italy
02/03/2026
Phase II
Randomised EValuation of Therapies for microvAscuLar Injury in STEACS – REVITALISE Study
2025-522060-32-00STEMI (ST elevated Myocardial Infarction)
CorFlow Therapeutics AG, CorFlow Therapeutics AG
Cardiovascular Diseases
Netherlands, Spain, France
02/03/2026
Phase III
Prospective Multicenter Randomized Non-Inferiority Study Comparing 7 Days Versus 14 Days of Antibiotic Treatment for Graft Pyelonephritis in Kidney Transplant Recipients (KTI)
2025-523120-53-00Graft pyelonephritis in kidney transplant recipients
Bellvitge University Hospital, Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL
Bacterial Infections and Mycoses
Spain
02/03/2026
Phase II
An open label extension study to evaluate the long-term safety and efficacy of subcutaneous lunsekimig in adult participants with asthma who participated in study DRI16762 or ACT18301
2025-522896-27-00Asthma
Sanofi-Aventis Recherche & Developpement
Respiratory Tract Diseases
Poland, Italy, Belgium, Sweden, Hungary, France, Germany, Spain, Denmark
02/03/2026
Phase II
A randomized, double-blind, placebo-controlled, Phase 2, dose-finding study to investigate the efficacy and safety of SAR445399 in participants with moderate to severe hidradenitis suppurativa
2025-522695-83-00Hidradenitis suppurativa
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Hungary, Spain, France, Belgium, Sweden, Germany, Italy
02/03/2026
Phase II
Efficacy and safety of Ursodeoxycholic Acid as a new therapy for the treatment of hepatorenal polycystic diseases, genetic study and determination of prognostic biomarkers.
2024-513644-28-00Hepatorenal polycystic diseases
Asociacion Instituto Biogipuzkoa
Digestive System Diseases
Spain
02/03/2026
Phase I/II
A Modular, Open Label, Dose Finding Phase 1/2 Clinical Trial in Patients with Solid Tumours to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PTT-4256 (RAISIC-1: Relief of Acidic Immune Suppression In Cancer)
2025-522944-41-00Solid Tumours
Pathios Therapeutics Limited
Not possible to specify
France, Spain
27/02/2026
Phase III
HighLiGHts - A Pivotal, Parallel-Arm, Phase 3, Open-Label, Active-controlled, Global, Multicenter, Randomized Basket Trial Investigating the Efficacy and Safety of Once-weekly Lonapegsomatropin Compared to Daily Somatropin in Prepubertal Children and Adolescents with Growth Failure or Short Stature due to Growth Hormone Sufficient Disorders – Turner Syndrome, SHOX Deficiency, Small for Gestational Age, and Idiopathic Short Stature
2025-523079-44-00Turner Syndrome (TS), idiopathic short stature (ISS), short…
Ascendis Pharma Endocrinology Division A/S
Musculoskeletal Diseases
Germany, Spain, Italy, France, Romania
27/02/2026
Phase III
A Phase III, Randomised, Open-Label, Multicentre Study of Datopotamab Deruxtecan or Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung17)
2024-520101-39-00TROP2 NMR-positive advanced or metastatic non-squamous non-…
AstraZeneca AB
Neoplasms
Spain, Poland, Hungary, Italy, Germany, France, Belgium, Austria
26/02/2026
Phase I
Phase 1 First-in-Human Study of JNJ-95566692 in Participants with NHLs
2025-523297-16-00Non-Hodgkin Lymphoid Malignancies (NHLs)
Janssen Cilag International
Neoplasms
Belgium, France, Spain
26/02/2026
Phase II
A Phase 2, Multicenter, Randomized, Double-blind Study of Safety and Efficacy of EL219 (Turletricin) versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy of Invasive Mould Infections (TREAT-1)
2025-522835-32-00Suspected Invasive Mould Infection
Elion Therapeutics Inc.
Bacterial Infections and Mycoses
Belgium, France, Spain, Italy
26/02/2026
Phase II
In vivo biological standardization of Olea europaea allergen extracts.
2025-523866-26-00Allergies
Asac Pharmaceutical Inmunology S.A.
Diagnosis
Spain
25/02/2026
Phase II
B7981118 - A Phase 2b Randomized, Double Blind, 12-Week Placebo Controlled Study With a 12-Week Double-Blind Extension Period to Evaluate the Efficacy, Safety and Tolerability of Ritlecitinib (PF 06651600) in Adult Participants with Chronic Spontaneous Urticaria
2025-522642-44-00CHRONIC SPONTANEOUS URTICARIA
Pfizer Inc.
Skin and Connective Tissue Diseases
Spain, Germany, Bulgaria, Poland
25/02/2026
Phase III
Studying Treatments in patients receiving androgen deprivation therapy (ADT) for Metastatic Prostate Cancer: Evaluation of Drug and radiation Efficacy: A 2nd multi-arm multi-stage randomised controlled trial (STAMPEDE2)
2025-522145-21-00Metastatic hormone sensitive prostate cancer
University College London
Neoplasms
Ireland, Germany, Spain
25/02/2026
Phase III
An Open-Label Study of Donidalorsen in Pediatric Patients Age 2 to Less than 12 Years Old with Hereditary Angioedema [Donidalorsen Treatment in Children with Hereditary Angioedema]
2025-523499-22-00Hereditary Angioedema (HAE)
Ionis Pharmaceuticals Inc.
Genetic Phenomena
Italy, Spain, Poland
25/02/2026
Phase III
A Phase 3, multicenter, open-label extension study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)
2025-522471-28-00psoriatic arthritis (PsA)
MoonLake Immunotherapeutics AG
Musculoskeletal Diseases
Estonia, Croatia, Slovakia, Lithuania, Romania, Hungary, Germany, France, Latvia, Poland, Portugal, Greece, Czechia, Bulgaria, Finland, Spain
25/02/2026
Phase II
Open-label, Uncontrolled, Multicenter Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Children From 2 Years to Less Than 18 Years of Age with Immunoglobulin G4 related Disease (IgG4-RD)
2025-520988-41-00Immunoglobulin G4 related Disease (IgG4-RD)
Amgen Inc.
Immune System Diseases
Greece, Poland, Italy, Spain
25/02/2026
Phase I/II
A Phase Ib/II, multi-site, open-label, two-part trial to evaluate the efficacy, safety, pharmacokinetics, and recommended combination dose of BNT324 with BNT327 in participants with advanced lung cancer
2024-520238-31-01Advanced Lung Cancer
BioNTech SE
Neoplasms
Spain, France, Italy, Poland
24/02/2026
Phase III
J2A-MC-GZPW: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Orforglipron on the Incidence of Major Adverse Cardiovascular Events in Participants With Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease
2025-523123-22-00Atherosclerosis Cardiovascular Disease, Chronic Kidney Dise…
Eli Lilly & Co.
Cardiovascular Diseases
Germany, Czechia, Lithuania, Spain, Austria, France, Hungary, Greece, Estonia, Netherlands, Slovakia, Poland, Romania, Bulgaria, Italy, Belgium
24/02/2026
Phase II
KEYMAKER-U01 Substudy 01J: A Randomized Phase 2 Umbrella Study With Rolling Arms of Investigational Agents for First-line Treatment of Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With KRAS G12C Mutations
2025-521939-36-00Participants with KRAS G12C-Mutant, Advanced or Metastatic …
Merck Sharp & Dohme LLC
Neoplasms
Italy, Poland, Spain, Finland, Netherlands, Greece
24/02/2026
Phase III
A multicenter, multinational, randomized, double-blind, placebo-controlled Phase 3, maintenance study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s disease
2025-521037-86-00Immune system diseases
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Spain, Czechia, Lithuania, Hungary, Greece, Bulgaria, Poland, Belgium, France, Germany, Norway, Austria, Netherlands, Italy, Slovakia
24/02/2026
Phase III
A multicenter, multinational, randomized, double-blind, placebo-controlled Phase 3, induction study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s Disease
2025-521036-11-00Immune system disseases
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Slovakia, Netherlands, Poland, Greece, Czechia, Italy, Bulgaria, Belgium, Germany, Lithuania, Austria, Spain, Hungary, Norway, France
24/02/2026
Phase II
J2R-MC-YAAD: A Phase 2, Double-blind, Placebo-Controlled Study to Evaluate LY3537021 for the Treatment of Chemotherapy-Induced Nausea and Vomiting in Adult Participants With Malignant Disease
2025-522204-24-00Neoplasms, Vomiting, Drug-Related Side Effects and Adverse …
Eli Lilly & Co.
Neoplasms
Romania, Spain, France, Italy
23/02/2026
Phase III
INCA000585-201 - A PHASE 2A, OPEN-LABEL, MULTI-CENTER STUDY OF TAFASITAMAB IN ADULT PARTICIPANTS WITH AUTOIMMUNE BLOOD CELL DISORDERS
2025-521286-27-00Immune-mediated thrombocytopenia, Autoimmune thrombocytopen…
Incyte Corp.
Hemic and Lymphatic Diseases
Netherlands, Italy, Spain, France
23/02/2026
Phase I/II
A Phase 1/2, Global, Open-Label, Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study
2022-502911-12-00Propionic Acidemia
Moderna Inc.
Nutritional and Metabolic Diseases
Spain, Netherlands, France
23/02/2026
Phase I
ADCX-020 for the treatment of patients with locally advanced or metastatic cancers
2025-523959-65-00Locally Advanced or Metastatic Solid Tumors
Adcytherix
Not possible to specify
Spain
23/02/2026
Phase III
A seamless Phase 2/3 randomized, open-label study to investigate efficacy and safety of frexalimab versus tacrolimus in adult kidney transplant recipients
2025-521521-33-00Kidney transplant rejection
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Germany, Hungary, Italy, Belgium, Czechia, Finland, Spain, Austria, Sweden, France, Denmark, Netherlands
23/02/2026
Phase III
Multicenter, Safety Follow-up Study to Assess Safety of Prior Treatment with Romosozumab in Children and Adolescents with Osteogenesis Imperfecta
2023-503293-21-00Osteogenesis Imperfecta
Amgen Inc.
Skin and Connective Tissue Diseases
Germany, Hungary, Italy, Belgium, Austria, Slovakia, Spain
23/02/2026
Phase III
Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination with Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients with Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia
2025-521314-25-00NPM1-m and KMT2A-r Acute Myeloid Leukemia
Kura Oncology Inc.
Neoplasms
Belgium, Spain, Italy, Czechia, Hungary, Poland, France, Portugal, Germany, Greece
20/02/2026
Phase II
Phase 2 study of iadademstat for the treatment of patients with essential thrombocythemia resistant/intolerant to hydroxyurea
2025-523864-19-00Essential Thrombocythemia
Oryzon Genomics S.A.
Hemic and Lymphatic Diseases
Spain
20/02/2026
Phase III
TRITON-PN: A Phase 3, Global, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Nucresiran in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy (hATTR-PN)
2025-522544-40-00Hereditary transthyretin-mediated amyloidosis with polyneur…
Alnylam Pharmaceuticals Inc.
Nervous System Diseases
France, Italy, Greece, Spain, Sweden, Ireland, Cyprus, Portugal, Germany
20/02/2026
Phase IV
Efficacy and tolerability of a simethicone-containing evacuating solution for colorectal cancer screening colonoscopy: a randomized parallel comparative trial. CLEAN+
2025-523748-11-00colorectal cancer early detection
Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer
Digestive System Diseases
Spain
20/02/2026
Phase I
A study to test different doses of BI 3923948 alone and in combination with an anti-PD-1 antibody in people with different types of advanced cancer (solid tumors)
2025-521438-27-00advanced, unresectable and/or metastatic solid tumors
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Neoplasms
Sweden, France, Spain, Germany
19/02/2026
Phase II
A phase II, multicentre, open label clinical trial evaluating the efficacy and safety of oral decitabine plus ivosidenib in adult patients with newly diagnosed acute myeloid leukemia older than 60 years old and/or who are ineligible for standard induction chemotherapy
2025-523238-17-00Acute myeloid leukemia
Fundacion PETHEMA
Neoplasms
Spain, Portugal
19/02/2026
Phase III
A Multicenter, 12-Month, Randomized, Double Blind, Placebo-Controlled Phase 3 Efficacy and Safety Study of Daily Oral LUM 201 in Naïve-to-Treatment, Prepubertal Children with Growth Hormone Deficiency (GHD)
2025-523820-26-00Growth Hormone Deficiency (GHD)
Lumos Pharma LLC
Hormonal diseases
Romania, France, Italy, Poland, Spain
18/02/2026
Phase II
Master Protocol Full Title: A Master Protocol for an Exploratory, Phase 2a, Proof-of-Concept Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis. ISA 1 Full Title: An ISA to Master Protocol ARGX-999-2-MG-2000 for an Exploratory, Phase 2a, Proof-of-Concept Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart IV as Add-On Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod.
2025-522492-28-00AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthe…
Argenx
Immune System Diseases
Spain, Poland, Germany, Netherlands, Greece, Italy, Belgium
18/02/2026
Phase I/II
A Phase 1b/2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate A) the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of IM-101 in Adult Participants with Generalized Myasthenia Gravis, and B) the Efficacy and Safety of Treatment of IM-101 in Adult Participants with Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
2025-522406-20-00Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
Immunabs Inc.
Nervous System Diseases
Bulgaria, Poland, Spain, Italy
18/02/2026
Phase III
A Phase 2/3, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Subjects with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
2025-520897-21-00Multiple Myeloma
AbbVie Deutschland GmbH & Co. KG
Neoplasms
Norway, France, Spain
18/02/2026
Phase III
A phase 3 randomized, double-blind, active-controlled study of palazestrant with ribociclib versus letrozole with ribociclib for the first-line treatment of ER+, HER2- advanced breast cancer (OPERA-02)
2025-522873-12-00ER+, HER2- Advanced Breast Cancer
Olema Pharmaceuticals Inc.
Neoplasms
Hungary, Portugal, Italy, France, Poland, Czechia, Germany, Spain, Belgium, Austria, Romania, Greece, Netherlands
17/02/2026
Phase I
Bioequivalence clinical trial of two formulations of rosuvastatin.
2026-525230-27-00Hypercholesterolemia
Laboratorios Alter S.A.
Cardiovascular Diseases
Spain
17/02/2026
Phase III
A randomized, double-blind, placebo-controlled study to evaluate efficacy and safety of early in hospital initiation of inclisiran treatment in patients with acute coronary syndromes: Victorion – RIDES
2025-521670-34-00Acute coronary syndrome (ST-elevation myocardial infarction…
Novartis Pharma AG
Cardiovascular Diseases
Germany, Hungary, Poland, France, Spain
16/02/2026
Phase III
A Phase 2/3, Randomized, Active-Controlled, Open-Label (Phase 2) and Double-Blind (Phase 3) Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) Once Daily in Treatment-Naïve Adult Participants Living With HIV 1
2025-522519-40-00HIV
Merck Sharp & Dohme LLC
Virus Diseases
France, Spain
16/02/2026
Rows per page Showing 501–600 of 1016
Previous 4 5 6 7 8 Next
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-europe/country/spain?page=6

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →

About this register

This register is built from the EU Clinical Trials Information System (CTIS), run by the European Medicines Agency: the single register for every trial authorised under the EU Clinical Trials Regulation (536/2014). CTIS held 12,490 trial records at the last sync on 25 Sep 2026, 03:16 UTC; this register shows the 2,500 most recently authorised of them, a stated recency window rather than the full archive. The list can be downloaded as CSV or JSON.

This page shows the 1,016 of those trials with a site in Spain.

How many recently authorised EU trials have a site in Spain?

1,016 of the 2,500 most recently authorised trials in this register list a site in Spain; 422 of them are Phase III. Trials are counted by authorisation on CTIS, not by recruitment status, which CTIS does not publish in the same form as ClinicalTrials.gov.

Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.